Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib in mutation-positive solid tumors
NCT03118817Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Belvarafenib in solid tumor, sponsored by Hanmi Pharmaceutical. Primary endpoint: Objective Response Rate up to 36 months. Started May 2017; status: completed.
02
Drugs
Belvarafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03118817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118817.